ema

News

Targeting COVID-19 and cancer with immunotherapy advancements

EU backs broader use of Comirnaty as COVID booster than US

The EMA has given the go-ahead to the use of Pfizer and BioNTech's COVID-19 vaccine Comirnaty as a booster for all people aged 18 or more, but says EU member states must decide for themselv

News

EMA looks at booster data for Pfizer/BioNTech COVID-19 jab

The EU regulator has started to review a marketing application filed by Pfizer and BioNTech for a third, booster dose of their Comirnaty COVID-19 vaccine given six months after the first co

R&D

COVID-19: Celltrion's therapeutic option

In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19.

News

scientifically visualization of a coronavirus spike protein

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May.

News

EMA finds possible link between mRNA COVID jabs and myocardi...

The EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based vaccines for COVID-19 and rare cases of heart inflammation.

News

EU okays BMS' azacitidine pill for first-line maintenance of...

Bristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that has been mainstay of acute myeloid leukaemia (AML) therapy for more tha

EU backs broader use of Comirnaty as COVID booster than US

EMA looks at booster data for Pfizer/BioNTech COVID-19 jab

COVID-19: Celltrion's therapeutic option

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

EMA finds possible link between mRNA COVID jabs and myocardi...

EU okays BMS' azacitidine pill for first-line maintenance of...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

ema

Editor's Picks